New drug cocktail aims to control Hard-to-Treat lymphoma

NCT ID NCT04646395

Ongoing Disease control Sponsor: International Extranodal Lymphoma Study Group (IELSG) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs, acalabrutinib and tafasitamab, in 26 patients with marginal zone lymphoma that has come back or not responded to previous treatment. The goal is to see how well the combo shrinks or controls the cancer and to check for side effects. Patients receive treatment for up to 24 cycles and are followed for about 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib and tafasitamab
What this could lead to: If successful, this combination could offer a new, effective treatment option for patients with marginal zone lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is a small, early-phase trial (26 patients) with no control group, so results may not be definitive. Side effects from the drug combination are possible and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

ASST Spedali Civili di Brescia

Brescia, Italy
AUSL Ravenna U.O. Ematologia

Ravenna, 48121, Italy
Azienda Ospedaliera - IRCCS - Arcispedale Santa Maria Nuova

Reggio Emilia, Italy
Fondazione IRCCS - Istituto Nazionale dei Tumori

Milan, Italy
Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico

Milan, Italy
Oncology Institute of Southern Switzerland

Bellinzona, 6500, Switzerland
Ospedale Maggiore della Carità

Novara, Italy
Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi

Varese, Italy
University of Wien

Vienna, 1190, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.